Harbin Medisan Pharmaceutical Co., Ltd.

Main research purpose: This study uses Olopatadine Hydrochloride Granules (Specification: 2.5 mg) produced by Lanxiha Sanlian Pharmaceutical Co., Ltd. as the test preparation, and Olopatadine Hydrochloride Granules [Specification: 0.5% (2.5 mg/0.5 g), trade name: Allelock®] produced by the original manufacturer Kyowa Kirin Co., Ltd. as the reference preparation to evaluate the bioequivalence of the test preparation and the reference preparation after administration under postprandial conditions. Secondary research purpose: To observe the safety of a single oral dose of 2.5 mg of Olopatadine Hydrochloride Granules test preparation or reference preparation in healthy subjects.

Main research purpose: This study used olopatadine hydrochloride granules (specification: 2.5 mg) produced by Lanxiha Sanlian Pharmaceutical Co., Ltd. as the test preparation, and olopatadine hydrochloride granules [specification: 0.5% (2.5 mg/0.5 g), trade name: Allelock®] produced by the original manufacturer Kyowa Kirin Co., Ltd. as the reference preparation to evaluate the bioequivalence of the test preparation and the reference preparation after administration under fasting conditions. Secondary study objective: To observe the safety of a single oral administration of 2.5 mg of the test preparation or reference preparation of olopatadine hydrochloride granules in healthy subjects.

(1) Primary study objective: To investigate the absorption rate and extent of the test preparation and the reference preparation under fasting and postprandial conditions after oral administration of a single dose of acetaminophen ibuprofen tablets (test preparation T, produced by Lanxiha Sanlian Pharmaceutical Co., Ltd., specification: each tablet contains 250 mg acetaminophen and 125 mg ibuprofen) and acetaminophen ibuprofen tablets (reference preparation R, licensed by Glaxosmithk Line Consumer Healthcare Homes US LLC, trade name: AdviL DuaL Action With Acetaminophen®, specification: each tablet contains 250 mg acetaminophen and 125 mg ibuprofen) to healthy Chinese participants, and to evaluate whether the test preparation and the reference preparation are bioequivalent. (2) Secondary study objective: To observe the safety of the test preparation and the reference preparation in healthy participants.